{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[14,2,14,3],[15,2,15,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910456238403321"]
[null,null,"Titolo",null,"Technology and health care in an era of limits [[electronic resource] /] / Annetine C. Gelijns, editor ; Committee on Technological Innovation in Medicine, Institute of Medicine"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academy Press, 1992"]
[null,null,"ISBN",null,"1-280-20320-X"]
[{"$nulls":4},"9786610203208"]
[{"$nulls":4},"0-309-56189-2"]
[{"$nulls":4},"0-585-02825-7"]
[null,null,"Descrizione fisica",null,"1 online resource (296 p.)"]
[null,null,"Collana",null,"Medical innovation at the crossroads ; ; v. 3"]
[null,null,"Disciplina",null,"362.1"]
[null,null,"Soggetti",null,"Managed care plans (Medical care)"]
[{"$nulls":4},"Medical care - United States"]
[{"$nulls":4},"Medical technology - Effect of managed care on - United States"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Papers presented at the third Institute of Medicine workshop \"The Changing Health Care Economy,\" held April 18-19, 1991, supported by the Howard Hughes Medical Institute, Pfizer, Inc., and the Health Industry Manufacturers Association."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"Technology and Health Care in an Era of Limits\"\"; \"\"Copyright\"\"; \"\"Acknowledgments\"\"; \"\"Contents\"\"; \"\"List of Abbreviations\"\"; \"\"Part I Setting the Stage\"\"; \"\"1 Introduction\"\"; \"\"References\"\"; \"\"2 Innovation and the Policies of Limits in a Changing Health Care Economy\"\"; \"\"THE SHAPE OF MEDICINE'S BENEFIT-UTILIZATION CURVE\"\"; \"\"WHICH RATE IS RIGHT?\"\"; \"\"REFORM OF THE DOCTOR-PATIENT RELATIONSHIP\"\"; \"\"LINKAGE BETWEEN THE SUPPLY OF RESOURCES AND MEDICINE'S IMPLICIT THEORIES OF EFFICACY\"\"; \"\"SEEKING LIMITS\"\"; \"\"INNOVATION AND THE POLICIES OF LIMITS\"\"; \"\"References\"\""]
[{"$nulls":4},"\"\"Part II Managing Care in the United States\"\"\"\"3 The Growth of Managed Care in the Private Sector\"\"; \"\"EMPLOYER-PROVIDED HEALTH CARE BENEFITS IN THE UNITED STATES\"\"; \"\"MANAGED CARE AND ITS GROWTH IN THE PRIVATE SECTOR\"\"; \"\"IMPLICATIONS OF MANAGED CARE FOR TECHNOLOGY DEVELOPMENT AND DISSEMINATION\"\"; \"\"References\"\"; \"\"4 Managing Medical Practice: The Potential of HMOs\"\"; \"\"MANAGING CARE AT GHC\"\"; \"\"BREAST CANCER SCREENING\"\"; \"\"THE "]
[{"$nulls":4},"HMO AS EFFECTIVENESS LABORATORY\"\"; \"\"CONCLUSION\"\"; \"\"References\"\"; \"\"5 Cost Containment Efforts in the Public Sector: Oregon's Priority List\"\""]
[{"$nulls":4},"\"\"RATIONALE AND BACKGROUND\"\"\"\"RANKING METHODOLOGY\"\"; \"\"RESULTS\"\"; \"\"DISCUSSION\"\"; \"\"ACKNOWLEDGMENTS\"\"; \"\"References\"\"; \"\"Part III Managing Care in the United Kingdom and Canada\"\"; \"\"6 Priority Setting in a Needs-based System\"\"; \"\"PROBLEMS OF THE BRITISH HEALTH CARE SYSTEM\"\"; \"\"THE \"\"REFORMED\"\" BRITISH HEALTH CARE SYSTEM\"\"; \"\"IMPLICATIONS FOR TECHNOLOGICAL ADVANCE IN MEDICINE\"\"; \"\"RATIONING HEALTH CARE: IS IT ETHICAL?\"\"; \"\"7 The Meeting of the Twain: Managing Health Care Capital, Capacity, and Costs in Canada\"\"; \"\"WHAT MAKES CANADIAN HEALTH CARE DIFFERENT?\"\"; \"\"SO HOW DOES CANADA DO IT?\"\""]
[{"$nulls":4},"\"\"Managing Operations\"\"\"\"Managing Capital\"\"; \"\"FROM MACRO- TO MICROMANAGEMENT AND BACK AGAIN?\"\"; \"\"THE FUTURE OF HEALTH CARE MANAGEMENT IN CANADA\"\"; \"\"References\"\"; \"\"Part IV Implications for Providers\"\"; \"\"8 New Technology Adoption in the Hospital\"\"; \"\"NEW TECHNOLOGY: WHAT ARE ITS COMPONENTS?\"\"; \"\"FACTORS INFLUENCING THE ADOPTION AND USE OF TECHNOLOGY\"\"; \"\"Method of Financing\"\"; \"\"Recovery of Operating Costs\"\"; \"\"Regulatory Equity\"\"; \"\"Level of Competition\"\"; \"\"Other Factors That Influence the Adoption of New Technology\"\"; \"\"Hidden New Technology\"\"; \"\"SUMMARY\"\"; \"\"REFERENCES\"\""]
[{"$nulls":4},"\"\"9 Physicians' Acquisition and Use of New Technology in an Era of Economic Constraints\"\"\"\"DIFFUSION OF MAGNETIC RESONANCE IMAGING INTO CLINICAL PRACTICE\"\"; \"\"Regulation of Magnetic Resonance Imaging Acquisition\"\"; \"\"The Food and Drug Administration\"\"; \"\"Certificate of Need Regulations\"\"; \"\"Reimbursement for Magnetic Resonance Imaging\"\"; \"\"Competition Over Magnetic Resonance Imaging\"\"; \"\"Summary: The Acquisition of Magnetic Resonance Imaging\"\"; \"\"TECHNOLOGY ACQUISITION IN THE \"\"NEW HEALTH CARE\"\" ERA\"\"; \"\"Nature of Technology\"\"; \"\"Hospitals and Regulation\"\"; \"\"Competition for Patients\"\""]
[{"$nulls":4},"\"\"Reimbursement\"\""]